Ozempic has gotten most of the name recognition associated with weight-loss drugs, it's not the only drug in this category ...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Eli Lilly fair value estimate is US$1,319 Current share ...

Eli Lilly (LLY) emerges among the top performers in Big Pharma in 2024 with obesity drug success, while Novo Nordisk (NVO) ...

Shares of Eli Lilly & Co. LLY sank 0.08% to $795.67 Tuesday, on what proved to be an all-around favorable trading session for ...

Investing in rapidly expanding biotech stocks can be a worthwhile long-term investment. Just one successful drug or device ...

Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase I for Adipocytic Sarcoma.

CFTX-1554 is under clinical development by Eli Lilly and Co and currently in Phase I for Peripheral Neuropathic Pain.

Lupin acquires Huminsulin from Eli Lilly to strengthen diabetes portfolio in India, offering affordable healthcare options.

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

The updates from clinical trials of Eli Lilly's competitors in the obesity market were largely underwhelming this year. See ...

What Eli Lilly ( LLY -0.05%) is doing is far more impressive. The company has been increasing its dividend at a high rate, ...

In a recent head-to-head study involving Novo Nordisk 's Wegovy, Zepbound came out on top, resulting in average weight loss ...